Al-Khazali Haidar M, Christensen Rune H, Gozalov Emil, Hakimzadeh Zahra, Melchior Anna G, Dominguez-Moreno Rogelio, Ashina Messoud, Ashina Håkan
Translational Research Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Cephalalgia. 2025 May;45(5):3331024251336132. doi: 10.1177/03331024251336132. Epub 2025 May 14.
ObjectiveTo determine whether intravenous infusion of substance P elicits headache and arterial dilation in healthy adults.MethodsIn a double-blind, placebo-controlled, two-way crossover study, we randomly allocated healthy adults to receive either substance P (1.5 pmol/kg/min) or placebo (isotonic saline) by 20-minute intravenous infusion on separate experiment days. The primary endpoint was the incidence of headache within 12 hours after the infusion. Other endpoints included the area under the curve (AUC) for headache intensity scores over the 12-hour observation period and AUC changes in the superficial temporal artery (STA) diameter from baseline to 120 minutes post-infusion.ResultsTwenty-one participants underwent randomization and completed both experiment days. Headache was reported by 15 (71%) of 21 participants following substance P, compared with two (10%) after placebo (< 0.001). The AUC for headache intensity scores was significantly higher after substance P infusion than after placebo (= 0.03). In addition, there was a significant STA diameter increase with substance P, compared with placebo (= 0.005).ConclusionsAmong healthy adults, substance P infusion elicited headache and arterial dilation. These findings support a role for substance P in headache pathogenesis and encourage further investigation in migraine and other headache disorders. Additional research is also needed to explore new therapeutic strategies targeting substance P or its downstream signaling.Trial Registration:CT identifier: NCT06632080.
目的
确定静脉输注P物质是否会在健康成年人中引发头痛和动脉扩张。
方法
在一项双盲、安慰剂对照、双向交叉研究中,我们将健康成年人随机分配,在不同的实验日通过20分钟静脉输注接受P物质(1.5 pmol/kg/分钟)或安慰剂(等渗盐水)。主要终点是输注后12小时内头痛的发生率。其他终点包括12小时观察期内头痛强度评分的曲线下面积(AUC)以及从基线到输注后120分钟颞浅动脉(STA)直径的AUC变化。
结果
21名参与者进行了随机分组并完成了两个实验日。21名参与者中有15名(71%)在接受P物质后报告头痛,而接受安慰剂后为2名(10%)(<0.001)。P物质输注后头痛强度评分的AUC显著高于安慰剂后(=0.03)。此外,与安慰剂相比,P物质使STA直径显著增加(=0.005)。
结论
在健康成年人中,输注P物质会引发头痛和动脉扩张。这些发现支持P物质在头痛发病机制中的作用,并鼓励对偏头痛和其他头痛疾病进行进一步研究。还需要额外的研究来探索针对P物质或其下游信号传导的新治疗策略。
CT标识符:NCT06632080。